

Index

- A**
- AKT
 γ chain family cytokine signaling, 9
 T-cell development role, 279
- AMPs. *See* Antimicrobial peptides
- Antimicrobial peptides (AMPs), 456
- Arid5a, 94
- Atopic dermatitis
 interleukin-17 studies, 130
 interleukin-22 therapeutic targeting, 169
- B**
- B cell
 γ chain family cytokine function, 16–18
 interferon- γ in activation, 226–227
 tumor necrosis factor in development and function, 105
- BCL11B, 280–281
- β Common family cytokines. *See also specific cytokines*
 cancer studies, 46
 functions, 43–44
 nervous system function, 46–47
 overview, 40–43
 receptors
 activation, 48–49, 51
 assembly, 48
 assembly, 48–51
 interactions with other receptors, 47–48
 proximal activation of signaling, 52–53
 sepsis and inflammation studies, 44–45
 therapy, 41–42, 53–56
- BLIMP1, 15
- Briakinumab, 151
- C**
- Candida albicans*, interleukin-17 studies, 129
- CAPS. *See* Cryopyrin-associated periodic syndromes
- Castleman disease, tocilizumab therapy, 89
- CD. *See* Crohn's disease
- Ciliary neurotrophic factor (CNTF)
 overview, 72–73
 mutations and disease, 76
 trans-signaling, 75
- CISH, 317–318
- CNTE. *See* Ciliary neurotrophic factor
- Crohn's disease (CD)
 γ chain family cytokine studies, 20
 interleukin-10 studies, 159, 161–162
 interleukin-22 therapy, 170–172
- CRS. *See* Cytokine release syndrome
- Cryopyrin-associated periodic syndromes (CAPS),
 262–263
- CTCL. *See* Cutaneous T-cell lymphoma
- Cutaneous T-cell lymphoma (CTCL), interleukin-15 role,
 448
- Cytokine release syndrome (CRS), interleukin-6 therapeutic
 targeting, 93, 94
- Cytokine studies
 agonist development, 458–459
 alarmins, 456–457
 antagonist development, 459–460
 assay development, 457
 definition, 455–456
 historical perspective, 456
 mimics, 457
 mutation studies, 458
 signaling studies, 457–458
- D**
- Daclizumab, 21
- DC. *See* Dendritic cell
- Dendritic cell (DC)
 classical dendritic cells
 cDC1 development and function, 397–398
 cDC2 development and function, 398–399
 GM-DCs, 403–404
 human cell features, 401–402
 identification
 mouse bone marrow, 396–397
 surface markers for in vivo identification, 403
 maturation, 404–406
 Mo-DCs, 403
 γ chain family cytokine function, 19
 interferon- γ in activation, 226
 long noncoding RNA regulation of differentiation,
 297–298
 plasmacytoid dendritic cells
 development and function, 399–400
 human cell features, 402
 subsets, 395
- Diabetes type 1, γ chain family cytokine studies, 20–21
- Diabetic foot ulcer (DFU), interleukin-20 family member
 therapy, 174–175
- E**
- Ectodysplasin, 104
- EPO. *See* Erythropoietin
- Erythropoietin (EPO), receptor, 47–48

Index

F

- Familial Mediterranean fever (FMF), 263–264
- FGK 4.5, 444
- FMF. *See* Familial Mediterranean fever
- Follicular lymphoma, interferon- α therapy, 437
- FOXP3, 11, 332

G

- γ Chain family cytokines. *See also specific cytokines*
 - autoimmune disease role, 19–22
 - B-cell function, 16–18
 - gene expression mediation, 9–10
 - natural killer cell function, 18–19
 - overview, 1–5
 - receptors, 5–7
 - signaling, 7–9
 - structure, 2
 - T-cell function
 - CD8⁺ T-cell development and differentiation, 16
 - development, 10–11
 - helper T-cell differentiation, 12–16
 - Tregs, 11–12
 - therapy, 22–25
- GATA3
 - helper T cells
 - differentiation role, 330–332
 - expression by noncanonical Th cell subtypes, 332–333
 - T-cell development role, 273–274, 277–280
- GCA. *See* Giant cell arteritis
- Giant cell arteritis (GCA), tocilizumab therapy, 92
- GM-CSF. *See* Granulocyte macrophage colony-stimulating factor
- Graft-versus-host disease (GVHD), interleukin-22
 - protective effects, 173–174
- Granulocyte macrophage colony-stimulating factor (GM-CSF)
 - cancer immunotherapy, 439–440
 - cancer studies, 46
 - functional overview, 43–44
 - nervous system function, 46–47
 - receptor, 48–53
 - sepsis and inflammation role, 45
 - therapeutic targeting, 53–55
- GVHD. *See* Graft-versus-host disease

H

- HEB, T-cell development role, 280–281
- Hepatitis
 - interferon- γ therapy, 176
 - interleukin-22 protective effects, 173
- HHV8. *See* Human herpes virus 8
- Human herpes virus 8 (HHV8), interleukin-6, 73

I

- ID2, 400
- IFN. *See* Interferon

- IFN- α . *See* Interferon- α
- IFN- γ . *See* Interferon- γ
- IL-1. *See* Interleukin-1
- IL-2. *See* Interleukin-2
- IL-3. *See* Interleukin-3
- IL-4. *See* Interleukin-4
- IL-5. *See* Interleukin-5
- IL-6. *See* Interleukin-6
- IL-7. *See* Interleukin-7
- IL-9. *See* Interleukin-9
- IL-10. *See* Interleukin-10
- IL-11. *See* Interleukin-11
- IL-12. *See* Interleukin-12
- IL-13. *See* Interleukin-13
- IL-15. *See* Interleukin-15
- IL-17. *See* Interleukin-17
- IL-19. *See* Interleukin-19
- IL-20. *See* Interleukin-20
- IL-21. *See* Interleukin-21
- IL-22. *See* Interleukin-22
- IL-23. *See* Interleukin-23
- IL-24. *See* Interleukin-24
- IL-26. *See* Interleukin-26
- IL-28. *See* Interleukin-28
- IL-29. *See* Interleukin-29
- IL-33. *See* Interleukin-33
- IL-37. *See* Interleukin-37
- ILC. *See* Innate lymphoid cell

Inflammation

- autoinflammatory disease. *See* Interleukin-1
 - β common family cytokine studies, 44–45
 - granulocyte macrophage colony-stimulating factor role, 45
 - interleukin-17 studies
 - IL-17B, 131
 - IL-17C, 131–132
 - IL-17D, 132
 - IL-17E, 132
 - tumor microenvironment, 414
 - tumor necrosis factor role, 103
- ### Innate lymphoid cell (ILC)
- cytokine regulation
 - group 1 cells, 382–383
 - group 2 cells, 383–385
 - group 3 cells, 385–387
 - interferon, 382–383
 - interleukin-1, 387
 - interleukin-2, 381–382, 386
 - interleukin-4, 384–385
 - interleukin-5, 384, 389
 - interleukin-7, 381–382, 386
 - interleukin-9, 384–385
 - interleukin-12, 388
 - interleukin-13, 384
 - interleukin-15, 381–382
 - interleukin-17, 386–387
 - interleukin-22, 386–387
 - overview, 380–382

- plasticity modulation, 387–388
 - tumor immunity, 388–389
 - functional overview, 379–380
 - subsets, 380
 - Th cell relationship, 335–336
 - Innate repair receptor (IRR), 47–48
 - Interferon (IFN)
 - cancer studies, 197
 - classes, 203–204, 206
 - classification, 436
 - innate lymphoid cell regulation, 382–383
 - long noncoding RNA regulation, 302–303
 - signaling, 196–197, 205
 - Interferon- α (IFN- α), cancer immunotherapy
 - follicular lymphoma, 437
 - Kaposi sarcoma, 437
 - melanoma, 437–438
 - toxicity, 438
 - Interferon- γ (IFN- γ)
 - antibodies, 457
 - cancer immunoeediting role
 - elimination phase, 229–231
 - equilibrium, 231–232
 - escape, 232–233
 - overview, 227–229
 - cancer studies, 176–177
 - cellular sources, 220–221
 - gene, 219
 - immune cell activation
 - B cell, 226–227
 - dendritic cell, 226
 - macrophage, 225–226
 - T cells
 - CD8⁺ T cells, 227
 - helper T cells, 227
 - Tregs, 227
 - interferon regulatory factor regulation, 211–212
 - posttranslational modification, 220
 - receptor
 - activation, 224
 - signaling pathway, 223, 225
 - structure and function, 221–223
 - types, 175
 - virus infection treatment, 175–176
 - Interferon regulatory factor (IRF)
 - interferon- γ regulation, 211–212
 - structure, 206
 - type I interferon regulation
 - cytosolic DNA recognition, 210–211
 - cytosolic RNA recognition, 208–210
 - Toll-like receptor signaling, 206–208
 - type III interferon regulation, 212
 - types, 206
 - Interleukin-1 (IL-1)
 - autoinflammatory disease studies
 - cryopyrin-associated periodic syndromes, 262–263
 - extrinsic inflammasomopathies, 265–267
 - familial Mediterranean fever, 263–264
 - interleukin-1 receptor antagonist deficiency, 265
 - intrinsic inflammasomopathies, 261–265
 - Majeed syndrome, 265
 - mevalonate kinase deficiency, 266
 - NLR4-associated autoinflammatory diseases, 264
 - NLRP12-associated autoinflammatory disorder, 265
 - overview, 261
 - pyogenic arthritis, pyoderma gangrenosum and acne syndrome, 265–266
 - tumor necrosis factor receptor-associated periodic syndrome, 267
 - cellular sources, 240–241
 - expression regulation, 246
 - family members, 239, 255–256
 - immune regulation, 245–246
 - immune stimulation by inflammasome-dependent cytokines, 260
 - inflammasome-dependent processing, 256–260
 - innate lymphoid cell regulation, 387
 - nuclear function, 248
 - overview, 239–240
 - signaling regulation, 247–248
- Interleukin-2 (IL-2)
 - autoimmune disease studies, 19–22
 - cancer immunotherapy
 - low-dose trials, 435–436
 - melanoma, 434–435
 - overview, 433–434
 - renal cell carcinoma, 434–435
 - CD8⁺ T cell
 - function, 16
 - response to virus infection, 362–365, 370, 372
 - functional overview, 2–3
 - helper T cell
 - differentiation role, 12–13, 15–16
 - fate determination, 329
 - history of study, 1–2
 - innate lymphoid cell regulation, 381–382, 386
 - natural killer cell function, 18
 - receptors, 1–2, 5–6
 - regulatory T-cell regulation, 346–350
 - therapy, 22–25
 - Treg function, 11–12, 14–15
- Interleukin-3 (IL-3)
 - cancer studies, 46
 - functional overview, 44
 - nervous system function, 46–47
 - receptor, 48–53
 - sepsis and inflammation role, 45
 - therapeutic targeting, 55
- Interleukin-4 (IL-4)
 - B-cell function, 16–18
 - functional overview, 3–4
 - innate lymphoid cell regulation, 384–385
 - macrophage function, 19
 - natural killer cell function, 18–19

Index

- Interleukin-4 (IL-4) (*Continued*)
 - receptors, 6
 - T helper cell differentiation role, 12–14, 329
 - therapy, 25
- Interleukin-5 (IL-5)
 - functional overview, 44
 - innate lymphoid cell regulation, 384, 389
 - nervous system function, 46–47
 - receptor, 48–53
 - therapeutic targeting, 55–56
- Interleukin-6 (IL-6)
 - antibodies, 457
 - cloning of complex components, 66–67
 - expression regulation, 86–87
 - family of cytokines. *See also specific cytokines*
 - mutations and disease, 75–76
 - overview, 72
 - plasticity, 72–73
 - human herpes virus 8, 73
 - overview, 64–66, 83–85
 - receptor complex
 - gp130 subunit, 69
 - signaling, 68–69, 85–86
 - soluble receptor, 73–74
 - structure, 68
 - trans-signaling, 69–71, 74–75
 - therapeutic targeting
 - cytokine release syndrome, 93, 94
 - rationale, 88–89
 - sepsis, 93–94
 - tocilizumab therapy
 - Castleman disease, 89
 - giant cell arteritis, 92
 - juvenile idiopathic arthritis, 90
 - myocardial infarction, 94
 - neuromyelitis optica, 92
 - polymyalgia rheumatica, 92–93
 - rheumatoid arthritis, 89–90
 - systemic sclerosis, 90–91
- Interleukin-7 (IL-7)
 - B-cell function, 16–18
 - functional overview, 4
 - innate lymphoid cell regulation, 381–382, 386
 - receptor, 6, 458
 - T-cell function
 - CD8⁺ T-cell function, 16, 365–368, 372–373
 - development role, 279–280
 - overview, 10–11
 - regulatory T-cell regulation, 351–353
- Interleukin-9 (IL-9)
 - functional overview, 4
 - innate lymphoid cell regulation, 384–385
 - receptors, 6
 - T helper cell differentiation role, 12–14
- Interleukin-10 (IL-10)
 - cancer
 - role, 165–166
 - therapeutic targeting, 166
 - cellular sources, 160
 - family members, 157–159
 - receptors, 158–159
 - structure, 158
 - systemic lupus erythematosus therapeutic targeting, 163
 - therapy
 - Crohn's disease, 159, 161–162
 - mechanism of action in autoimmune disease, 159
 - rheumatoid arthritis, 162–163
 - strategies
 - antibody-conjugated IL-10, 164–165
 - bacteria expression for intestinal delivery, 163–164
 - ulcerative colitis, 159, 161
- Interleukin-11 (IL-11)
 - mutations and disease, 75–76
 - trans-signaling, 75
- Interleukin-12 (IL-12)
 - cancer immunotherapy, 438–439
 - cancer studies
 - antitumor immunity, 141
 - cross-regulation with interleukin-23, 148–150
 - receptor expression, 144–145
 - therapeutic targeting, 150
 - family members, 139
 - innate lymphoid cell regulation, 388
 - overview, 139–140
- Interleukin-13 (IL-13), innate lymphoid cell regulation, 384
- Interleukin-15 (IL-15)
 - cancer immunotherapy
 - clinical trials, 442–443
 - combination therapy, 443–444
 - immune response, 441–442
 - optimization, 443
 - overview, 440–441
 - preclinical studies, 441
 - toxicity, 441
 - CD8⁺ T cell
 - function, 16
 - response to virus infection, 368–370, 372–373
 - cutaneous T-cell lymphoma role, 448
 - dendritic cell function, 19
 - functional overview, 4–5
 - innate lymphoid cell regulation, 381–382
 - receptors, 6
 - regulatory T-cell regulation, 353–354
- Interleukin-17 (IL-17)
 - cellular sources
 - IL-17A, 122–123
 - IL-17B, 124
 - IL-17C, 124
 - IL-17D, 124
 - IL-17E, 123–124
 - IL-17F, 122
 - infection studies
 - IL-17A, 129
 - IL-17E, 132
 - IL-17F, 128–129

- inflammation studies
 - IL-17B, 131
 - IL-17C, 131–132
 - IL-17D, 132
 - IL-17E, 132
 - innate lymphoid cell regulation, 386–387
 - overview of family, 121–122
 - signaling
 - IL-17A, 124–125
 - IL-17B, 126
 - IL-17C, 126
 - IL-17D, 126
 - IL-17E, 125–126
 - IL-17F, 124–125
 - overview, 124
 - regulation, 127–128
 - skin disease studies, 129–131
 - Interleukin-19 (IL-19), cellular sources, 160
 - Interleukin-20 (IL-20)
 - cellular sources, 160
 - diabetic foot ulcer management, 174–175
 - psoriasis role and therapeutic targeting, 168–169
 - rheumatoid arthritis role and therapeutic targeting, 169–170
 - Interleukin-21 (IL-21)
 - autoimmune disease studies, 19–22
 - B-cell function, 16–18
 - cancer immunotherapy, 439
 - CD8⁺ T-cell function, 16
 - dendritic cell function, 19
 - functional overview, 5
 - natural killer cell function, 18–19
 - receptors, 7
 - T helper cell differentiation role, 15–16
 - Interleukin-22 (IL-22)
 - atopic dermatitis therapeutic targeting, 169
 - cellular sources, 160
 - inflammatory bowel disease therapy, 170–172
 - innate lymphoid cell regulation, 386–387
 - protective effects
 - graft-versus-host disease, 173–174
 - hepatitis, 173
 - pancreatitis, 173
 - psoriasis role and therapeutic targeting, 168–169
 - Interleukin-23 (IL-23)
 - cancer studies
 - cellular sources, 142, 144
 - clinical relevance of expression, 142–143
 - cross-regulation with interleukin-12, 148–150
 - receptor expression, 144–147
 - therapeutic targeting, 150
 - tumor promotion, 141–142, 145, 147–148
 - tumor suppression, 142
 - overview, 139–140
 - Interleukin-24 (IL-24)
 - antitumor activity, 166–168
 - cellular sources, 160
 - Interleukin-26 (IL-26), cellular sources, 160
 - Interleukin-28 (IL-28), cellular sources, 160
 - Interleukin-29 (IL-29), cellular sources, 160
 - Interleukin-33 (IL-33)
 - cancer studies, 245
 - cellular sources, 240–241
 - expression regulation, 246
 - nuclear function, 248
 - overview, 239–240
 - regulatory T-cell regulation, 354–355
 - signaling regulation, 247–248
 - T helper cell responses
 - Th1, 242–243
 - Th2, 241–242
 - visceral adipose tissue homeostasis role, 243–244, 355
 - wound healing role, 244–245
 - Interleukin-37 (IL-37)
 - cellular sources, 240
 - nuclear function, 248
 - IPEX syndrome, 332
 - IRF. *See* Interferon regulatory factor
 - IRR. *See* Innate repair receptor
- J**
- JAK
 - β common family cytokine signaling, 51–52
 - γ chain family cytokine signaling, 7, 9
 - overview of JAK-STAT pathway, 187–189, 314–315
 - therapeutic targeting, 25
 - therapeutic targeting in cancer, 444–447
 - JIA. *See* Juvenile idiopathic arthritis
 - Juvenile idiopathic arthritis (JIA), tocilizumab therapy, 90
- K**
- Kaposi sarcoma, interferon-α therapy, 437
 - KIT, T-cell development role, 277, 279, 282–284
- L**
- lncRNA. *See* Long noncoding RNA
 - Long noncoding RNA (lncRNA)
 - cell differentiation role with cytokines
 - dendritic cell, 297–298
 - erythrocytes, 296
 - hematopoiesis, 295–296
 - macrophage, 297
 - short-lived myeloid cells, 296–297
 - T cells
 - CD8⁺ T cell, 298
 - NeST, 298, 301
 - Th1, 298, 301
 - Th2, 301
 - Th17, 301
 - Treg, 302
 - cytokine production regulation by lncRNAs
 - AS-IL-1α, 305
 - IL-1β-RBT46, 305
 - lnc-IL-7R, 305

Index

- Long noncoding RNA (lncRNA) (*Continued*)
 lncRNA-Cox2, 304
 lncRNA-EPS, 306
 NEAT1, 305
 NKILA, 305
 PACER, 304–305
 THRIL, 304
 cytokine regulation of RNAs
 interferon, 302–303
 tumor necrosis factor α , 302
 diseases, 306–307
 overview, 293–295
 prospects for study, 307–308
 therapeutic targeting, 307
- M**
- Macrophage. *See also* Tumor-associated macrophage
 interferon- γ in activation, 225–226
 long noncoding RNA regulation of differentiation, 297
Majeed syndrome, 265
Melanoma
 interferon- α therapy, 437–438
 interleukin-2 therapy, 434–435
Morbid, 296
MS. *See* Multiple sclerosis
Multiple sclerosis (MS)
 β common family cytokines studies, 45
 γ chain family cytokine studies, 21
MYB, T-cell development role, 282
Myocardial infarction, toclizumab therapy, 94
- N**
- Natural killer cell, β chain family cytokine function, 18–19
NEAT1, 305
NeST, 298, 301, 303
Neuromyelitis optica (NMO), toclizumab therapy, 92
Neutrophil. *See* Tumor-associated neutrophil
NLRC4, 259–261, 264
NLRP3, 258–263
NLRP12-associated autoinflammatory disorder, 265
NMO. *See* Neuromyelitis optica
Notch, T-cell development role, 274, 276, 282
NRAV, 303
NRON, 303
NRP1, 386
- P**
- PACER, 304–305
Pancreatitis, interleukin-22 protective effects, 173
PMR. *See* Polymyalgia rheumatica
Polymyalgia rheumatica (PMR), toclizumab therapy, 92–93
PRC2, 294
Psoriasis
 interleukin-17 studies, 129–130, 132
 interleukin-20 role and therapeutic targeting, 168–169
 interleukin-23 therapeutic targeting, 151
PSTPIP1, 266
PTEN, 346
Pyogenic arthritis, pyoderma gangrenosum and acne
 (PAPA) syndrome, 265–266
- R**
- RA. *See* Rheumatoid arthritis
Regulatory T cell. *See* T cell
Renal cell carcinoma, interleukin-2 therapy, 434–435
Rheumatoid arthritis (RA)
 γ chain family cytokine studies, 20–21
 interleukin-10 studies, 162–163
 interleukin-17 studies, 131
 interleukin-20 role and therapeutic targeting, 169–170
 toclizumab therapy, 89–90
RNA. *See* Long noncoding RNA
ROR γ t, Th cell studies
 differentiation role, 331–332
 expression by noncanonical Th cell subtypes, 332–333
- S**
- Sepsis
 β common family cytokine studies, 44–45
 interleukin-6 therapeutic targeting, 93–94
SLE. *See* Systemic lupus erythematosus
SOCS
 SOCS1
 functional overview, 316
 genome-wide association studies, 320
 promoter hypermethylation and tumorigenesis, 320
 T-cell regulation
 antitumor immunity, 319–320
 differentiation, 314
 Tregs, 315
 SOCS3
 cancer studies, 321
 functional overview, 192, 316, 320–321
 genome-wide association studies, 321
 helper T-cell regulation, 321
 types, 315–316
SSc. *See* Systemic sclerosis
STAT
 chromatin remodeling, 194–195
 γ chain family cytokine signaling, 7–9
 gene expression mediated, 9–10
 interferon signaling, 196–197
 intracellular localization, 194
 mutations
 gain-of-function mutations
 cancer, 195
 infectious disease, 195–196
 types, 195
 negative regulation, 192
 overview, 187–189
 overview of JAK-STAT pathway, 314–315
 posttranslational modifications
 glycosylation, 192

- lysine and arginine, 191–192
- phosphorylation
 - serine, 189
 - STAT1, 190
 - STAT2, 190
 - STAT3, 190
 - STAT5A, 190
 - STAT5B, 190
 - STAT6, 190–191
 - tyrosine, 192
- SUMOylation, 192
- Th cell fate determination, 328–330
- therapeutic targeting in cancer, 444–447
- unphosphorylated STATs
 - gene expression regulation
 - negative, 193–194
 - positive, 192–193
 - overview, 192
 - U-STAT3 in mitochondria, 194
- Systemic lupus erythematosus (SLE)
 - γ chain family cytokine studies, 20
 - interleukin-10 therapeutic targeting, 163
- Systemic sclerosis (SSc), tocilizumab therapy, 90–91

- T**
- TACI, 109
- TAM. *See* Tumor-associated macrophage
- TAN. *See* Tumor-associated neutrophil
- T cell
 - CD8⁺ T-cell response to virus infection
 - acute infection, 361–362
 - chronic infection, 370–372
 - interleukin-2, 362–365, 370, 372
 - interleukin-7, 365–368, 372–373
 - interleukin-15, 368–370, 372–373
 - CISH in differentiation, 317–318
 - development
 - cell precursor flux regulation, 282–286, 280
 - commitment in early development
 - phase 1, 278–279
 - phase 2, 280–281
 - phase 3, 281–282
 - early phases
 - phase 1, 274
 - phase 2, 274–275
 - phase 3, 275–276
 - GATA3 role, 277–278
 - initiation by environmental signals and transcription factors, 276
 - interleukin-7 in phase 1/phase 2 transition, 279–280
 - overview, 273–274
 - γ chain family cytokine function
 - CD8⁺ T-cell development and differentiation, 16
 - development, 10–11
 - T helper cell differentiation, 12–16
 - Tregs, 11–12
 - helper T cell
 - differentiation
 - cross-regulation, 332
 - cytokine-mediated positive feedback, 330
 - STATs in fate determination, 328–330
 - transcription factors, 330–332
 - effector T-cell relationship with Tfh cells, 334–335
 - epigenetics and cell plasticity, 333–334
 - functions by type, 328
 - innate lymphoid cell relationship, 335–336
 - types and cytokine production, 327–328
 - interferon- γ in activation
 - CD8⁺ T cells, 227
 - helper T cells, 227
 - Tregs, 227
 - interleukin-33 and T helper cell responses
 - Th1, 242–243
 - Th2, 241–242
 - long noncoding RNA regulation of differentiation
 - CD8⁺ T cell, 298
 - NeST, 298, 301
 - Th1, 298, 301
 - Th2, 301
 - Th17, 301
 - Treg, 302
 - regulatory T-cell differentiation and homeostasis
 - control by cytokines
 - interleukin-2, 346–350
 - interleukin-7, 351–353
 - interleukin-15, 353–354
 - interleukin-33, 354–355
 - overview, 345–346
 - therapeutic targeting, 355–356
 - transforming growth factor β , 350–351
 - SOCS regulation
 - SOCS1
 - antitumor immunity, 319–320
 - differentiation, 314
 - Tregs, 315
 - SOCS3 and helper T cells, 321
 - tumor necrosis factor in development and function, 104
 - TCF1, 274, 277, 282
 - TGF- β . *See* Transforming growth factor β
 - THRIL, 304
 - Thymic stromal lymphoprotein (TSLP), 329, 351, 353
 - TLRs. *See* Toll-like receptors
 - TNE. *See* Tumor necrosis factor
 - Tocilizumab, therapy
 - Castleman disease, 89
 - giant cell arteritis, 92
 - juvenile idiopathic arthritis, 90
 - myocardial infarction, 94
 - neuromyelitis optica, 92
 - polymyalgia rheumatica, 92–93
 - rheumatoid arthritis, 89–90
 - systemic sclerosis, 90–91
 - Toll-like receptors (TLRs), type I interferon regulation via interferon regulatory factor, 206–208

Index

- TRAF3, 347
TRAIL, 417, 421–422
Transforming growth factor β (TGF- β)
 regulatory T-cell regulation, 350–351
 Th cell fate determination, 329–330
TRAPS. *See* Tumor necrosis factor receptor-associated periodic syndrome
TSLP. *See* Thymic stromal lymphoprotein
Tumor necrosis factor (TNF)
 functions
 adaptive immunity, 104
 B-cell development and function, 105
 bone homeostasis, 103–104
 brain, 105
 cell death, 103
 ectodermal development, 104
 inflammation, 103
 lymphoid organs, 104
 overview of family, 99–103
 survival signaling, 103
 T-cell development and function, 104
 wound healing, 103
 long noncoding RNA regulation of tumor necrosis factor α , 302
 noncanonical coreceptors and ligands, 111–112
 prospects for study, 114
 regulation, 111, 113–114
 signaling
 bidirectional signaling, 107
 induced juxtaposition, 105–107
 membrane anchoring of ligand and receptor, 107–108
 pathways, 111
 protein-binding motifs, 110–111
 re-anchoring, 107, 109–110
 Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), 267
 Tumor-associated macrophage (TAM)
 anticancer therapeutic response, 421–423
 biomarker utilization in cancer, 419–421
 overview, 413
 tumor growth and progression role, 415–416
 Tumor-associated neutrophil (TAN)
 anticancer therapeutic response, 421–423
 biomarker utilization in cancer, 419–421
 tumor growth and progression role, 416–419
- U**
UC. *See* Ulcerative colitis
Ulcerative colitis (UC)
 γ chain family cytokine studies, 20
 interleukin-10, 159, 161
 interleukin-22 therapy, 170–172
Ustekinumab, 151
- V**
Vascular endothelial growth factor (VEGF), 418, 459
VAT. *See* Visceral adipose tissue
VEGF. *See* Vascular endothelial growth factor
Visceral adipose tissue (VAT), interleukin-33 in homeostasis, 243–244, 355
- X**
Xist, 294
X-linked severe combined immunodeficiency (XSCID), *IL2RG* mutations, 2
XSCID. *See* X-linked severe combined immunodeficiency